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DOI 10.1186/s13058-015-0623-yRESEARCH ARTICLE Open AccessChromosomal copy number alterations for
associations of ductal carcinoma in situ
with invasive breast cancer
Anosheh Afghahi1†, Erna Forgó2†, Aya A. Mitani1, Manisha Desai1, Sushama Varma2, Tina Seto1, Joseph Rigdon1,
Kristin C. Jensen2,3, Megan L. Troxell4, Scarlett Lin Gomez5,6, Amar K. Das1,7, Andrew H. Beck8,
Allison W. Kurian1,5* and Robert B. West2*Abstract
Introduction: Screening mammography has contributed to a significant increase in the diagnosis of ductal
carcinoma in situ (DCIS), raising concerns about overdiagnosis and overtreatment. Building on prior observations
from lineage evolution analysis, we examined whether measuring genomic features of DCIS would predict
association with invasive breast carcinoma (IBC). The long-term goal is to enhance standard clinicopathologic
measures of low- versus high-risk DCIS and to enable risk-appropriate treatment.
Methods: We studied three common chromosomal copy number alterations (CNA) in IBC and designed fluorescence
in situ hybridization-based assay to measure copy number at these loci in DCIS samples. Clinicopathologic data were
extracted from the electronic medical records of Stanford Cancer Institute and linked to demographic data from the
population-based California Cancer Registry; results were integrated with data from tissue microarrays of specimens
containing DCIS that did not develop IBC versus DCIS with concurrent IBC. Multivariable logistic regression analysis was
performed to describe associations of CNAs with these two groups of DCIS.
Results: We examined 271 patients with DCIS (120 that did not develop IBC and 151 with concurrent IBC) for the
presence of 1q, 8q24 and 11q13 copy number gains. Compared to DCIS-only patients, patients with concurrent IBC
had higher frequencies of CNAs in their DCIS samples. On multivariable analysis with conventional clinicopathologic
features, the copy number gains were significantly associated with concurrent IBC. The state of two of the three copy
number gains in DCIS was associated with a risk of IBC that was 9.07 times that of no copy number gains, and the
presence of gains at all three genomic loci in DCIS was associated with a more than 17-fold risk (P = 0.0013).
Conclusions: CNAs have the potential to improve the identification of high-risk DCIS, defined by presence of
concurrent IBC. Expanding and validating this approach in both additional cross-sectional and longitudinal cohorts
may enable improved risk stratification and risk-appropriate treatment in DCIS.Introduction
Screening mammography is responsible for most diag-
noses of asymptomatic ductal carcinoma in situ (DCIS)
[1–3], raising concern for overtreatment of this nonle-
thal disease. In contrast to invasive breast carcinoma (IBC),* Correspondence: akurian@stanford.edu; rbwest@stanford.edu
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(http://creativecommons.org/publicdomain/zeradiation therapy (RT) has not demonstrated a survival
benefit for DCIS [4], yet clinical trial subset analyses have
failed to identify a patient subgroup that derives no
recurrence-free survival (RFS) benefit; similarly, we cannot
identify which DCIS patients benefit from adjuvant endo-
crine therapy [5–7]. Understanding how DCIS evolves to
IBC, in terms of genomic progression and temporal pro-
gression, may provide insight into addressing these screen-
ing issues.
We and others have previously performed genome-wide
sequencing studies on progression of breast neoplasia,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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oma. These studies indicate that there is a gradual somatic
gain of copy number alterations (CNAs) and single nu-
cleotide variations (SNVs) [8–12]. Our studies have exam-
ined hyperplasia, DCIS and IBC from cross-sectional
samples, by both targeted sequencing [12] and whole
genome sequencing [10], to identify genomic changes
that occur in progression from these pathologically
defined neoplasias. These data have identified specific
genomic changes to pathologic lesions defined by
morphology whose risks have previously been studied at
an epidemiologic level [13], including common CNAs and
SNVs that have been identified in IBC [14, 15]. These grad-
ual genomic changes provide an opportunity to predict
which DCIS lesions are likely to be associated with pro-
gression to IBC.
It is well recognized that risk stratifying DCIS is challen-
ging because of its clinical and biological heterogeneity. An
additional problem when considering genetic relationships
(lineage analysis) and generating genetic biomarkers of risk,
is that the standard of surgical care for DCIS is that the
entire lesion is removed. Thus, studies that examine the
recurrence of DCIS or emergence of IBC are not likely to
directly address the genetic relationships between DCIS
and IBC that are essential to our understanding as to
how cancer develops genetically. A cross-sectional study
(examining concurrent DCIS and IBC) addresses this issue
directly. The natural genetic relationships of concurrent
DCIS and IBC are preserved and have not been altered by
treatments. These cross-sectional samples provide a good
way to test potential genetic biomarkers, such as somatic
SNVs and CNAs, on a large cohort.
A number of studies have previously examined the risk
of DCIS recurrence using protein expression markers [16];
however, DNA copy number changes are common in early
genomic lesions and may serve as more robust biomarkers
due to their insensitivity to intratumoral factors such as
hypoxia. In this study, we examined the accumulation of
CNAs as a biomarker for developing IBC in noninvasive
neoplasia. We generated a theoretical analysis of SNV and
CNA frequencies in DCIS through a simulation experi-
ment based on IBC data from The Cancer Genome Atlas
(TCGA) [14]. Since genomic change appears to correlate
with progression [9], we aimed to study these changes in a
large cohort at the level of the preinvasive DCIS lesion,
and to characterize its association with clinical and demo-
graphic data [17, 18]. These findings may enable the devel-
opment of molecular tools for DCIS risk stratification,
which is an urgent clinical need.
Methods
Data resource environment and patient identification
All available cases with enough tissue for sampling were
identified in the Department of Pathology at StanfordUniversity Hospital (SUH) from 2000 to 2007 with the
diagnosis of either DCIS and no development of IBC
over a median follow-up of 9 years or DCIS with con-
current IBC present, based on per protocol assessment
by SUH pathologists. Surgical samples with sufficient
tissue were collected with Health Insurance Portability
and Accountability Act (HIPAA)-compliant Stanford
University Institutional Review Board (IRB) approval
(Protocol number 19482 and 22825). Because archival
tissue was used, a waiver of consent was obtained. All
research was approved by SUH and the State of California
IRB (for use of state cancer registry data).
Clinical data extraction and data addition
Using Oncoshare, a multisource data resource for breast
cancer outcomes research, we extracted clinical data from
SUH electronic medical records (EMRs) (Epic Systems,
Verona, WI, USA) and from a SUH warehouse for clinical
data collected before Epic implementation in 2007, the
Stanford Translational Research Integrated Database En-
vironment (STRIDE), as previously published [17, 18]. We
requested state cancer registry (California Cancer Registry,
CCR) records for all patients with breast cancer treated at
SUH from 2000 through 2011. CCR and EMR records
were linked using names, social security numbers, medical
record numbers, and birthdates. All personal identifying
information was removed [18].
Simulation analysis of SNV and CNA frequencies as
predictors of invasive carcinoma in DCIS
We performed a simulation experiment to provide insight
into the types of genomic alterations (in terms of both fre-
quency and magnitude of association with IBC) that are
most likely to be useful in a genomic predictor of IBC risk
in DCIS. To construct a simulated genomic dataset, we
based the sample size on the number of samples available
in our study set (151 cases and 129 controls). We then cre-
ated frequency-based classes of genomic alterations in
DCIS and classes of differential frequencies between cases
that progressed to IBC and controls that did not. We based
our DCIS frequency classes on preliminary data for
SNV/CNA frequencies in TCGA [14], as little is cur-
rently known about SNV/CNA frequencies in DCIS.
We first created three frequency-based classes of gen-
omic alterations in DCIS: low frequency (5 %), mid
frequency (15 %), and high frequency (30 %), and four
classes of differential frequencies between cases and
controls: highly differential (alteration frequency is
threefold higher in cases versus controls), moderately
differential (alteration frequency is 1.5-fold higher in cases
versus controls), low-level differential (alteration is 1.25-
fold higher in cases versus controls), and nondifferential
(alteration frequency is generated from the same distribu-
tion in cases and controls). Based on data for SNV/CNA
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of our alterations as low frequency (this group is represen-
tative of low-frequency breast cancer alterations such as
MLL3 mutation, PTEN mutation and GATA3 mutation),
27 % (six of 22) as moderate frequency (representative of
moderate frequency breast cancer alterations such as
11q13 gain, 8q24 gain, ERBB2 gain and CDH1 mutation),
and 27 % (six of 22) as high frequency (representative of
common breast cancer alterations such as TP53 mutation,
PIK3CA mutation, 1q gain, 8q gain, 16p gain, 20q gain,
16q deletion, 17p deletion, 8p deletion, and 22q deletion,
among other common arm-level CNAs) in the simulated
DCIS samples. We modeled nine of the 22 features (41 %)
as deriving from distributions with differential frequency
in the cases versus controls. These nine features were
equally distributed across the nine possible permutations
of frequency (low, moderate, high) and magnitude of case
versus control differential (low, moderate, high).
For each of 2000 iterations, we first constructed simu-
lated case and control data sets (as described above). We
then used L1-regularized logistic regression to build a pre-
dictor and performed tenfold cross-validation to select the
optimal value for the λ tuning parameter. For each of the
2000 iterations, we recorded the overall model performance
(area under the curve (AUC) on held-out cases in cross-
validation for the top-performing value of λ), the number
of active features in the top-performing model, and the
population-wide frequency (low frequency, moderate fre-
quency, high frequency) and underlying distribution (non-
differential, low-level differential, moderately differential,
highly differential) that gave rise to the active features.Patient population and samples
Patient surgical samples diagnosed at SUH between 2000
and 2007 were selected for the presence of DCIS and con-
structed into a tissue microarray (TMA, TA-239) based on
a previously described protocol [19, 20]. The size of the
DCIS was not obtained. In brief, two experienced breast pa-
thologists (KJ and RW) reevaluated the grading for this
study and the criteria used included architectural pattern
and the presence of necrosis. Samples were excluded due
to paucity of material or poor preservation of material. The
TMA contained one representative 0.6 mm core from 280
clinically independent tumors, 151 samples of DCIS only,
and 129 samples of DCIS with concurrent IBC. Sampling
of DCIS in close proximity to, or intermixed with extensive
invasive cancer was avoided. A total of 271 patients with
DCIS only (120 cases) or DCIS and IBC (151 cases) were
included in the final analysis. Note that there were seven
cases that contributed two gene profiles and one case that
contributed three gene profiles. For the primary analysis,
we used all 280 samples. As a sensitivity analysis, we ran-
domly selected one sample from each case that contributedmore than one gene profile, and used a total of 271 samples
corresponding to the 271 unique patients.Patient characteristics
In the 271 patients (280 samples) with DCIS, most were
40–64 years old and diagnosed from 2000 to 2003. Most
(73.4 %) of patients were non-Hispanic (NH) white, with
19.6 % Asian/Pacific Islander, 3.7 % Hispanic, and 1.5 %
NH black. Half (50.6 %) of the cases expressed hormone re-
ceptors (HR), and the most common grade was 2 (48 %).
Among DCIS with IBC cases that had HR and human epi-
dermal growth factor receptor 2 (HER2) status recorded,
there was a roughly equivalent distribution between HR-
positive HER2-negative (29.1 %), HER2-positive (35.8 %),
and HR-negative, HER2-negative (triple-negative, 22.5 %)
subtypes (Table 1 and see Additional file 1). HER2 gain was
present in 30.8 % of the DCIS-only cases and 34.4 % of the
DCIS with concurrent invasive cancer cases (Table 1).
Treatments and outcomes varied somewhat by invasive-
ness: unilateral mastectomy was performed among 23.3 %
DCIS-only and 31.1 % of DCIS with IBC patients, whereas
bilateral mastectomy was performed among 20.8 % of
DCIS-only and 27.8 % of DCIS with IBC patients. The rates
of these surgical therapies are consistent with a study by
Worni et al. where they found the rate of unilateral mastec-
tomies in DCIS patients to be 23.4 % [21]. Only 8.3 % of
DCIS-only patients were dead as of 2013, versus 19.9 % of
DCIS with IBC patients (see Additional file 2).Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed
to examine chromosome 1q32, 8q24 and 11q13 gains. The
genomic loci targeted were chosen based on the simulation
results (see Results) and their frequency in invasive cancers
from The Cancer Genome Atlas (TCGA) data [14]. We
used 4 μm formalin-fixed, paraffin-embedded sections cut
from the constructed TMA, based on a protocol previously
described [22]. Briefly, BAC clones RP11-1044H13 (1q32),
RP11-1136L8 (8q24.21) and RP11-94L15 (17q12) were ob-
tained from the BACPAC Resources Center (Children’s
Hospital Oakland Research Institute, Oakland, CA, USA),
while clone CTD-2537F6 (11q13.3) was acquired from
Invitrogen/Life Technologies (Grand Island, NY, USA).
Probe RP11-1044H13 (1q32), RP11-1136L8 (8q24.21)
and CTD-2537F6 (11q13.3) were labeled with Cy3
dUTP (cat number PA53022 GE Healthcare, Pittsburgh,
PA, USA) and control probes RP11-1120M18 (3q25)
and CTD-2344F21 (2q37) were labeled with AlexaFluor
647-aha-dUTP (cat number A32763 Life Technologies)
and Green dUTP (cat number 02N32-050 Abbot Mo-
lecular, Des Plaines, IL, USA), respectively using the Nick
Translation Kit (cat number 07J00-001 Abbot Molecular).
Table 1 Characteristics of 271 patients with ductal carcinoma in situ (DCIS), with and without invasive breast cancer
DCIS
All patients DCIS only DCIS with invasive cancer
N (%) N (%) N (%)
Total 271 (100.0) 120 (100.0) 151 (100.0)
Age at diagnosis, years
<40 24 (8.9) 4 (3.3) 20 (13.2)
40–49 90 (33.2) 43 (35.8) 47 (31.1)
50–64 90 (33.2) 36 (30.0) 54 (35.8)
≥65 67 (24.7) 37 (30.8) 30 (19.9)
Year of breast cancer diagnosis
2000–2003 226 (83.4) 97 (80.8) 129 (85.4)
2004–2007 43 (15.9) 22 (18.3) 21 (13.9)
2008–2011 2 (0.7) 1 (0.8) 1 (0.7)
Race
Missing 5 (1.8) 2 (1.7) 3 (2.0)
Hispanic 10 (3.7) 4 (3.3) 6 (4.0)
Non-Hispanic (NH) white 199 (73.4) 81 (67.5) 118 (78.1)
NH black 4 (1.5) 3 (2.5) 1 (0.7)
NH Asian/Pacific Islander 53 (19.6) 30 (25.0) 23 (15.2)
Socioeconomic status
Missing 30 (11.1) 19 (15.8) 11 (7.3)
1 (Lowest) 4 (1.5) 2 (1.7) 2 (1.3)
2 15 (5.5) 8 (6.7) 7 (4.6)
3 23 (8.5) 9 (7.5) 14 (9.3)
4 40 (14.8) 10 (8.3) 30 (19.9)
5 (Highest) 159 (58.7) 72 (60.0) 87 (57.6)
Hormone receptors
Missing 12 (4.4) 0 0 12 (7.9)
Either ER or PR positive 137 (50.6) 65 (54.2) 72 (47.7)
Both ER and PR negative 122 (45.0) 55 (45.8) 67 (44.4)
Stage
Missing 4 (1.5) 0 0 4 (2.6)
Stage 0 120 (44.3) 120 (100.0) 0 0
Stage I 69 (25.5) 0 0 69 (45.7)
Stage II 69 (25.5) 0 0 69 (45.7)
Stage III 8 (3.0) 0 0 8 (5.3)
Stage IV 1 (0.4) 0 0 1 (0.7)
Grade
Missing 2 (0.7) 1 (0.8) 1 (0.7)
1 56 (20.7) 27 (22.5) 29 (19.2)
2 130 (48.0) 57 (47.5) 73 (48.3)
3 83 (30.6) 35 (29.2) 48 (31.8)
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Table 1 Characteristics of 271 patients with ductal carcinoma in situ (DCIS), with and without invasive breast cancer (Continued)
HER2 gain
No gain 182 (67.2) 83 (69.2) 99 (65.6)
Gain 89 (32.8) 37 (30.8) 52 (34.4)
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
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Imaging and analysis were performed using Ariol 3.4v soft-
ware (Genetix/Leica Microsystems, San Jose, CA, USA).
Fluorescence was scored visually using filters Cy3dUTP
(green: 550 nm), AF 647 dUTP (red: 647 nm), and Green
dUTP (yellow: 488 nm). Within the DCIS cells, total signals
for each color within a given slide region were counted. In-
vasive carcinoma cells and nonneoplastic cells were ex-
cluded from the analysis. Signals from 100 cells per sample
were counted, when possible, with a minimum of 40 cells
counted in all cases. The test probes were individually hy-
bridized with the two control probes for each genomic
locus to determine copy number gain. Total test probe
green counts (1q32, 8q24.21, 11q13.11 or 17q12) were
compared with red (3q25) and yellow (2q37) control
counts, which are frequently unaltered in breast cancer
[14, 15]. The signals were scored according to two pa-
rameters; signals per cell and ratio of test probe to con-
trol probes. Only the DCIS components were scored
and compared across cases, which were either DCIS
alone or DCIS with concurrent IBC. Cases were scored
as heterogeneous if at least 25 % of the scored DCIS
cells had a different signal call. Cases were scored as
gained if the target to control probe ratio was greater
than 1.5 or the number of test signals was greater than
three per cell. This scoring criterion was based on our
previous study where we examined the HER2 copy number
in a large cohort of breast cancers and a gain of greater
than 1.5 was the cutoff value that most correlated with a
worse outcome [23]. Cases were scored as deleted if the
target to control probe ratio was less than 0.75, or greater
than 25 % of the DCIS cells scored had a target to control
probe ratio of less than 0.75. For consistency, we scored
HER2 gain according to the criteria above set forth for the
three genomic loci investigated.
Immunohistochemistry
HER2 immunoreactivity was evaluated by immunohis-
tochemistry (IHC). The TMA were cut into 4-μm-thick
sections, deparaffinized, hydrated, subjected to Cell
Conditioning 1 (CC1, Ventana Medical Systems, Tuscon,
AZ, USA) antigen retrieval and stained with a prediluted
anti-HER2 antibody (Rabbit, Clone 4B5, Ventana Medical
Systems number 790-2991) using an automated immunos-
tainer. HER2 expression was scored according to the 2013
American Society of Clinical Oncology/College of American
Pathologists HER2 Test recommendations [24].Statistical analyses
We used logistic regression techniques to characterize the
association between copy number gains at three loci and
IBC among patients with DCIS. The multivariable model
on which our primary analysis was based additionally in-
cluded age at diagnosis, race, and hormone receptor sta-
tus, grade of the DCIS component and HER2 gain in
order to gauge the association of copy number status and
IBC after adjusting for demographics and relevant clinical
variables. A complete-case analysis was based on a model
that included subjects who had data on all variables speci-
fied (N = 158). As a sensitivity analysis, we additionally
employed multiple-imputation methods with ten imputed
data sets (mi impute chained in Stata) to retain all subjects
in the study even if they were missing one of the variables
specified in the model (N = 271) (Stata Statistical Soft-
ware. Release 13. StataCorp LP, College Station, TX, USA).
A two-sided Wald test was conducted at the 0.05 level to
assess the significance of the association. Odds ratios and
95 % confidence intervals were used to characterize the
magnitude of the association. As a sensitivity analysis, we
randomly selected one sample for cases with multiple
gene profiles and repeated the logistic regression analyses
with 154 cases in the complete case analysis and 271 cases
in the analysis that employed multiple imputation.
Results
Simulation analysis of SNV and CNA frequencies as
predictors of invasive carcinoma in DCIS
We conducted a simulation experiment to determine
the types of genomic characteristics (based on frequency
and association with IBC) most likely to be useful fea-
tures in a predictive model of DCIS risk in IBC. The re-
sults from this analysis suggest that genomic features
with moderate-to-high overall frequency (15–30 %) and
high differential frequency between cases versus controls
(threefold) are likely to be selected as active features in
the predictive model, while lower frequency alterations
and alterations with weaker associations with IBC are
much less likely to be informative in a risk-prediction
model (Fig. 1). For example, the simulated genomic fea-
tures with moderate-to-high frequency and strong asso-
ciation with IBC were selected in ≥ 99 % of the
iterations, while simulated genomic features with strong
association with IBC but low population frequency were
selected in only 65 % of the models (Fig. 1). The fre-
quency of recurrent genomic alterations in IBC varies
Fig. 1 Genomic predictor simulation experiment. We created three frequency-based classes of genomic alterations in ductal carcinoma in situ
(DCIS): low frequency (LF) (5 %), mid frequency (MF) (15 %), and high frequency (HF) (30 %), and four classes of differential frequencies between
cases and controls: highly differential (HD) (alteration frequency is threefold higher in cases versus controls), moderately differential (MD) (alteration
frequency is 1.5-fold higher in cases versus controls), low-level differential (LD) (alteration is 1.25-fold higher in cases versus controls), and nondifferential
(ND) (alteration frequency is generated from the same distribution in cases and controls). For each of 2000 simulations, we used L1-regularized logistic
regression to build a predictor and performed tenfold cross-validation to select the optimal value for the λ tuning parameter. For each simulation, we
recorded which types of features in terms of frequency (LF, MF, HF) and differential status (ND, LD, MD, HD) were active in the model. The results are
displayed in the figure, with the feature types along the X-axis and the proportion of simulations in which each feature type was active in the model
along the Y-axis
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SNVs occurring at a frequency greater than 5 % while
more than 30 CNAs occur at a frequency greater than
15 % [15].
Based on our modeling results, we expect that the ma-
jority of genomic features in a successful genomic classi-
fier will be CNAs with fewer, if any, SNVs. As such, we
decided to investigate the association between three of
the most common and recurrent IBC-associated CNAs
(gains of genomic regions of 1q, 8q24, and 11q13) and
IBC risk in DCIS.
Univariate exploratory analyses of chromosomal gains in
DCIS with or without invasive cancer
We examined the presence of copy number gains in
three chromosomal loci, 1q, 8q24, and 11q13, by FISH
in 280 samples diagnosed as DCIS only (122 cases with
no development of IBC over a median follow-up period
of 9 years), or DCIS plus IBC (158 cases) (Table 2)
arrayed on a TMA. We chose to study a set of loci (1q,
8q24, and 11q13) which have a high frequency of copy
number gains (>30 %) among at least two molecularbreast cancer subtypes [14, 15]. The prevalence gains in
all three genomic loci in the two groups of DCIS to-
gether were lower than values previously reported in
IBC [15]. Overall copy number gain frequency was as
follows: 1q at 52 % (compared to 64 % in IBC [15]),
8q24 at 44 % (compared to 60 % in IBC [15]), and 11q13
at 20 % (compared to 32 % in IBC [15]). Low copy num-
ber gains (one to two additional copies) represented the
vast majority of copy number alterations at 1q and 8q24
(80 % and 78 %, respectively). In contrast, 11q13 had
roughly equal numbers of low (53 %) and high (47 %
with > 2 additional copies) gains (Fig. 2). When stratify-
ing DCIS on whether there was concurrent IBC or not,
we found increased genomic gains in DCIS with concur-
rent IBC (in comparison to DCIS alone) in all three re-
gions when examined individually; in combinations; and
with all three copy number gains. The prevalence of
copy number gain was higher in DCIS with concurrent
IBC versus DCIS alone across all three genomic loci in-
dividually (1.35- to 3-fold), in combinations, and with all
three copy number gains (Table 2). We examined the
co-existence of HER2 gain and the other three loci gains
Table 2 Chromosomal gains in ductal carcinoma in situ (DCIS) with and without invasive cancer
DCIS type
All patients DCIS only DCIS with invasive cancer
N (%) N (%) N (%)
Total 280 (100.0) 122 (100.0) 158 (100.0)
1q gains
No signal 80 (28.6) 35 (28.7) 45 (28.5)
No 96 (34.3) 49 (40.2) 47 (29.7)
Yes 104 (37.1) 38 (31.1) 66 (41.8)
8q24 gains
No signal 63 (22.5) 27 (22.1) 36 (22.8)
No 121 (43.2) 63 (51.6) 58 (36.7)
Yes 96 (34.3) 32 (26.2) 64 (40.5)
11q13 gains
No signal 74 (26.4) 32 (26.2) 42 (26.6)
No 143 (51.1) 71 (58.2) 72 (45.6)
Yes 63 (22.5) 19 (15.6) 44 (27.8)
HER2 gains
No 188 (67.1) 84 (68.9) 104 (65.8)
Yes 92 (32.9) 38 (31.1) 54 (34.2)
1q and 8q24 gains
No signal 94 (33.6) 43 (35.2) 51 (32.3)
No 133 (47.5) 63 (51.6) 70 (44.3)
Yes 53 (18.9) 16 (13.1) 37 (23.4)
1q and 11q13 gains
No signal 108 (38.6) 46 (37.7) 62 (39.2)
No 138 (49.3) 67 (54.9) 71 (44.9)
Yes 34 (12.1) 9 (7.4) 25 (15.8)
1q and HER2 gains
No signal 80 (28.6) 35 (28.7) 45 (28.5)
No 145 (51.8) 66 (54.1) 79 (50.0)
Yes 55 (19.6) 21 (17.2) 34 (21.5)
8q24 and 11q13 gains
No signal 87 (31.1) 37 (30.3) 50 (31.6)
No 159 (56.8) 78 (63.9) 81 (51.3)
Yes 34 (12.1) 7 (5.7) 27 (17.1)
8q24 and HER2 gains
No signal 63 (22.5) 27 (22.1) 36 (22.8)
No 163 (58.2) 74 (60.7) 89 (56.3)
Yes 54 (19.3) 21 (17.2) 33 (20.9)
11q13 and HER2 gains
No signal 74 (26.4) 32 (26.2) 42 (26.6)
No 165 (58.9) 78 (63.9) 87 (55.1)
Yes 41 (14.6) 12 (9.8) 29 (18.4)
1q and 8q24 and 11q13 gains
No signal 112 (40.0) 49 (40.2) 63 (39.9)
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Table 2 Chromosomal gains in ductal carcinoma in situ (DCIS) with and without invasive cancer (Continued)
No 146 (52.1) 68 (55.7) 78 (49.4)
Yes 22 (7.9) 5 (4.1) 17 (10.8)
1q and 8q24 and HER2 gains
No signal 94 (33.6) 43 (35.2) 51 (32.3)
No 150 (53.6) 66 (54.1) 84 (53.2)
Yes 36 (12.9) 13 (10.7) 23 (14.6)
1q and 11q13 and HER2 gains
No signal 105 (37.5) 44 (36.1) 61 (38.6)
No 140 (50.0) 68 (55.7) 72 (45.6)
Yes 35 (12.5) 10 (8.2) 25 (15.8)
8q24 and 11q13 and HER2 gains
No signal 113 (40.4) 44 (36.1) 69 (43.7)
No 167 (59.6) 78 (63.9) 89 (56.3)
All four gains
No signal 112 (40.0) 49 (40.2) 63 (39.9)
No 148 (52.9) 68 (55.7) 80 (50.6)
Yes 20 (7.1) 5 (4.1) 15 (9.5)
Mutually exclusive categories
Unable to determine 112 (40.0) 49 (40.2) 63 (39.9)
No gains 43 (15.4) 29 (23.8) 14 (8.9)
1q only 31 (11.1) 15 (12.3) 16 (10.1)
8q24 only 19 (6.8) 8 (6.6) 11 (7.0)
11q13 only 8 (2.9) 4 (3.3) 4 (2.5)
Two of three gains 45 (16.1) 12 (9.8) 33 (20.9)
All three gains 22 (7.9) 5 (4.1) 17 (10.8)
Fig. 2 a Hematoxylin and eosin (H&E) image of ductal carcinoma in situ (DCIS) with 11q13 gain. b Fluorescence in situ hybridization (FISH) image
of DCIS with high level of copy number gain
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frequency of HER2 was 32.9 %. The prevalence of HER2
gain was higher in DCIS with concurrent IBC versus
DCIS alone (Table 2).
After finding the chromosomal gains of 1q, 8q24 and
11q13 to be increased in DCIS in the setting of IBC com-
pared to DCIS only, we tested whether these gains are as-
sociated with IBC (Table 3 and see Additional file 3). We
found statistically significant differences in distribution of
copy number gains between the two diagnostic groups in
all three regions when examined individually, in combin-
ation, and with all three copy number gains. The sensitiv-
ity for each of the three regions alone ranged from 37.9 to
58.4 %, with high specificity for the combinations of gains
of 1q and 11q13 (88.2 %); 8q24 and 11q13 (91.8 %); and
all three copy number gains (93.2 %). The combination of
8q24 and 11q13 gains demonstrated the highest positive
predictive values at 79.4 %. When we examined the co-
existence of copy number gains of HER2 and the other
three genomic loci, we found a statistically significant dif-
ference in the frequency distribution between the two
diagnostic groups for the cytogenetic combination of 1q,
11q13 and HER2 (p = 0.038, Table 3). The sensitivity for
this combination performed at the low end when com-
pared to the three copy number gain combinations at
25.8 %, with a specificity of 87.2 % and a negative pre-
dictive value of 48.6 % (Table 3).
Multivariable logistic regression and classifier analyses
predicting invasive cancer among DCIS cases
To characterize the association between DCIS and IBC, we
applied multivariable models of IBC as a function of a six-Table 3 Performance of cytogenetic combinations as predictors of
Chromosomal region gains 1q 8q24 11q13 HER2 1q and
8q24
1q
11q
All cases 200.0 217.0 206.0 280.0 186.0 172
DCIS plus invasive
cancer (IBC)
113.0 122.0 116.0 158.0 107.0 96.0
DCIS only (no IBC) 87.0 95.0 90.0 122.0 79.0 76.0
True positive 66.0 64.0 44.0 54.0 37.0 25.0
False negative 47.0 58.0 72.0 104.0 70.0 71.0
False positive 38.0 32.0 19.0 38.0 16.0 9.0
True negative 49.0 63.0 71.0 84.0 63.0 67.0
Sensitivity 58.407 52.459 37.931 34.177 34.579 26.0
Specificity 56.322 66.316 78.889 68.852 79.747 88.1
Positive
predictive value
63.462 66.667 69.841 58.696 69.811 73.5
Negative
predictive value
51.042 52.066 49.650 44.681 47.368 48.5
Fisher’s exact
test, two-tailed
0.046 0.006 0.010 0.610 0.034 0.02
DCIS ductal carcinoma in situ, IBC invasive breast cancerlevel categorical variable describing chromosomal gains at
regions 1q, 8q24 and 11q13, along with age at diagnosis,
race, hormone receptor status, histological grade and the
presence of HER2 gain (Table 4 and see Additional file 4).
The association between copy number gain and IBC was
statistically significant in both complete-case analysis and
multiple-imputation (MI) analysis (p = 0.0013, 0.0001, re-
spectively) and shows that subjects with gains at all three
loci are 18 times more likely to have an IBC diagnosis than
subjects without gains at these loci; subjects with exactly
two copy number gains are nine times more likely to have
an IBC diagnosis, and subjects with 8q24 gain only are 4.2
times more likely to have IBC than subjects with no gain in
these regions (MI analysis). Interestingly, the genomic copy
number gain, age at diagnosis and HER2 gain were the only
statistically significant variables in the model. Of note,
HER2 gain is not significantly associated with invasive can-
cer in the univariate analysis, but is inversely associated in
the multivariate analysis, in which subjects with HER2 copy
number gain were significantly less likely to have an IBC
diagnosis (odds ratio 0.47, p = 0.039), when compared to
DCIS alone (Table 4). In addition, we examined HER2
“high” amplification (defined as > 10 copies per nucleus)
and HER2 strong positivity (defined as 3+ IHC staining)
and neither of these variables was significantly associated
with invasive cancer on either univariate or multivari-
ate analyses.
Discussion
This study demonstrates that genomic changes can act
as a risk stratifier for DCIS, predicting the presence of
concurrent IBC. We observed no significant differencesinvasive breast cancer
and
13
1q and
HER2
8q24 and
11q13
8q24 and
HER2
11q13 and
HER2
1q and 8q24
and 11q13
All
four
.0 200.0 193.0 217.0 206.0 168.0 168.0
113.0 108.0 122.0 116.0 95.0 95.0
87.0 85.0 95.0 90.0 73.0 73.0
34.0 27.0 33.0 29.0 17.0 15.0
79.0 81.0 89.0 87.0 78.0 80.0
21.0 7.0 21.0 12.0 5.0 5.0
66.0 78.0 74.0 78.0 68.0 68.0
42 30.088 25.0 27.049 25.000 17.895 15.789
58 75.862 91.765 77.895 86.667 93.151 93.151
29 61.818 79.412 61.111 70.732 77.273 75.000
51 45.517 49.057 45.399 47.273 46.575 45.946
2 0.425 0.002 0.432 0.052 0.040 0.094
Table 4 Univariate and multivariable logistic regression analyses predicting invasive breast cancer among ductal carcinoma in situ
(DCIS) cases
Univariate Multivariable (complete cases = 158) Multiple imputation (all cases = 280)
OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
Gene category 0.0027 0.0013 0.0001
No gain 1.00 1.00 1.00
1q only 2.21 (0.85, 5.71) 1.96 (0.68, 5.67) 4.60 (1.77, 11.91)
8q24 only 2.85 (0.94, 8.66) 4.23 (1.15, 15.50) 4.24 (1.27, 14.11)
11q13 only 2.07 (0.45, 9.52) 2.51 (0.42, 15.00) 3.17 (0.65, 15.47)
Two of three gains 5.70 (2.27, 14.27) 9.07 (2.93, 28.11) 7.91 (2.79, 22.41)
All three gains 7.04 (2.16, 23.00) 17.96 (3.92, 82.24) 14.23 (3.56, 57.79)
Age at diagnosis, years 0.015 0.0527 0.0253
<40 3.38 (1.07, 10.64) 3.60 (0.74, 17.50) 4.60 (1.28, 16.49)
40–49 0.69 (0.38, 1.23) 0.46 (0.19, 1.12) 0.71 (0.37, 1.38)
50–64 1.00 1.00 1.00
≥65 0.57 (0.31, 1.08) 0.70 (0.26, 1.89) 0.68 (0.33, 1.39)
Race 0.092 0.1478 0.3085
Non-Hispanic (NH) white 1.34 (0.50, 3.61) 3.99 (0.70, 22.70) 1.56 (0.51, 4.76)
NH Asian/Pacific Islander 0.68 (0.23, 2.04) 2.10 (0.31, 14.23) 0.91 (0.25, 3.29)
Other 1.00 1.00 1.00
Hormone receptors 0.4896 0.6824 0.4258
ER and/or PR positive 1.00 1.00 1.00
Both ER and PR negative 1.19 (0.73, 1.92) 1.18 (0.53, 2.61) 1.26 (0.71, 2.25)
Grade 0.9263 0.8397 0.5300
1 1.00 1.00 1.00
2 1.13 (0.61, 2.08) 0.93 (0.36, 2.40) 0.73 (0.36, 1.52)
3 1.12 (0.57, 2.18) 0.73 (0.23, 2.29) 0.62 (0.26, 1.46)
HER2 any gain 0.5926 0.0102 0.0386
No 1.00 1.00 1.00
Yes 1.15 (0.69, 1.90) 0.29 (0.12, 0.75) 0.47 (0.23, 0.96)
ER estrogen receptor, PR progesterone receptor
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IBC in standard clinicopathologic factors of race, hor-
mone receptor status and histological grade. By contrast,
we did find significantly higher frequencies for copy
number gains at 1q, 8q24 and 11q13 with any two of
three genomic loci and all three genomic loci in pa-
tients with DCIS and concurrent invasive cancer when
compared to DCIS only. Multivariable analysis showed
that gains at the three regions were significantly asso-
ciated with IBC among patients with DCIS, after ad-
justment for important clinical variables including grade,
hormone receptor status and even HER2 copy number
gain, which was associated with a lower risk of having inva-
sive cancer and is consistent with prior publications on
DCIS [25]. Furthermore, we show that this is a feasible
method, utilizing standardized FISH techniques, and as
such has high potential to address the critical unmet needfor accurate risk stratification and personalized treatment
of DCIS.
Population-wide screening mammography has largely
created the problem of diagnosing asymptomatic DCIS
[1–3]; concerns about overtreatment have lent support
for replacing “DCIS” with “ductal intraepithelial neoplasia”,
emphasizing the indolent behavior of many of these lesions
[26]. However, since we cannot predict which DCIS lesions
will progress to invasive cancer, treatment guidelines recom-
mend mastectomy or breast-conserving therapy plus RT,
followed by adjuvant tamoxifen: this approach is excessive
treatment for most patients [7, 27–30]. Previous attempts at
risk stratification, using protein expression markers such as
p16, Ki67 and COX [16], or an RT-PCR assay that estimates
the risk of local recurrence [31], are limited by problems of
intratumoral variability and reliance upon IBC rather than
DCIS for gene selection. Some genetic changes occur early
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most of the neoplastic population at more advanced
stages like DCIS [10]. DNA copy number changes are
common in early genomic lesions and may be more ro-
bust as biomarkers than gene expression levels, which
can be subject to heterogeneity due to intratumoral fac-
tors such as hypoxia. At the molecular level, CNAs and
SNVs have been described previously in breast cancer
[14, 15], and their application and integration into clin-
ical practice is appealing. Our present modeling results
show that CNAs are more likely to be prognostic than
SNVs based on their frequency in IBC [15].
Our approach aimed to optimize practicality for ultim-
ate translation to patient care. We used TMA technology
because the amount of DCIS in each core is similar to the
amount present in conventional breast biopsies. We used
FISH to measure CNAs as this approach can generate
single-cell measurements in a complex tumor micro-
environment with multiple cell types present. Although
molecular techniques are sensitive for detection and
quantification at the SNV level [32], critical morphological
correlation is lost. Our use of FISH on TMAs avoids this
limitation, resulting in more precise genomic copy number
data. The FISH technique is also currently used in the clinics
to measure HER2 in breast cancer (and other more subtle
genomic alterations in other neoplasia) and thus this ap-
proach may be easily adopted by most clinical laboratories.
Our cross-sectional study approach has limitations and
advantages over a longitudinal approach. While a cross-
sectional study does not allow for the evaluation of re-
currence, we have a median follow-up of 9 years for the
DCIS-only cases, a timeframe consistent with previous
studies examining the recurrence rates of DCIS [33].
While the challenges of clinical biomarker assessment
will ultimately be addressed with longitudinal cohorts
of DCIS that progress over time to IBC, longitudinal
cohorts do not address the genetic relationships be-
tween DCIS and IBC that are essential to our under-
standing as to how cancer develops. The problem with
longitudinal cohorts is that the initial DCIS should be
entirely removed at the time of the definitive surgical
treatment. Therefore, the resulting subsequent recur-
rence, either DCIS or IBC, is likely not directly related
to the primary DCIS. Given that the surgical treatment
of the primary DCIS is to entirely remove the DCIS but
not necessarily remove potentially related lesions of
lesser risk (e.g., hyperplasias), a longitudinal DCIS co-
hort study would be more reflective of the risk poten-
tial of the associated lesser risk lesions that are not
entirely removed. Alternatively, the recurrence may be
directly related to the primary DCIS if the surgical resection
is incomplete. However, genetic biomarkers generated from
this scenario would not be related to intrinsic features of
the primary DCIS but rather more complex treatmenteffects such as the clinical and radiologic appreciation of
the extent of the disease. It is also possible that a clonally
related neoplastic precursor, such as atypical ductal hyper-
plasia or columnar cell change, is present at the surgical
margin and that residual part of this lesion progresses to
the recurrent carcinoma. This would explain the observa-
tion that the recurrences typically occur in the same quad-
rant of the breast. This scenario is compatible with our
lineage evolutionary tree analyses as determined by whole
genome sequencing, where we can identify precursors in
both columnar cell lesions and atypical ductal hyperplasia
that are clonally related to both the concurrent ductal car-
cinoma in situ and the invasive carcinoma [10]. It is also
possible that there is a nonneoplastic field effect, localized
to that quadrant that is responsible for the recurrence.
Additional studies on the lineages of the initial and recur-
rent lesions will be required to understand this fully. The
main limitation of this cross-sectional approach is that it
does not address the important clinical scenario of whether
a patient with DCIS alone will eventually develop IBC. This
is clearly an important question to address. However, as
noted above, this question is less about the intrinsic fea-
tures of DCIS than about the features of the neoplasia (e.g.,
hyperplasia) that remains unresected at the time of defini-
tive surgery. Prior to tackling that question, it is useful to
identify, on an evolutionary level, whether genomic changes
within DCIS and its evolutionary ancestors predict the de-
velopment of IBC. From this perspective of identifying fea-
tures in DCIS that predict risk, a cross-sectional study is
appropriate as the natural evolutionary relationships be-
tween DCIS and IBC are retained.
Although the FISH assay we developed did identify high-
risk DCIS cases, there are multiple subtypes of IBC and
likely multiple corresponding subtypes of DCIS, and as
such different combinations of markers may be needed for
risk stratification of different DCIS subtypes. Our under-
standing of the different pathways involved in the develop-
ment of IBC and specific genomic alterations therein is
growing. Low- and high-grade neoplasias demonstrate dif-
ferent CNAs [34]. In addition, PIK3CA mutation occurs
early in oncogenesis and is associated with ductal hyperpla-
sias, while TP53 mutations at early stages have not been
found [35, 12]. Furthermore, NOTCH/MAST fusions have
been described in cases of DCIS associated with IBC [36].
This growing knowledge will serve to guide future studies
of the approach we present here.
Conclusions
In conclusion, our proof-of-principle study demonstrates
the feasibility of a novel genomic predictor of breast can-
cer risk using data derived from TCGA, and characterizes
its performance in the context of patient demographic
and clinical factors. The three FISH assays for 1q, 8q24
and 11q13 positively identified a subset of high-risk DCIS
Afghahi et al. Breast Cancer Research  (2015) 17:108 Page 12 of 13patients; if expanded and validated in prospective trials,
this approach, which can be integrated into routine clin-
ical practice readily, may ultimately improve the care of
patients with early breast neoplasia.
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